Literature DB >> 19729475

Involvement of sphingosine 1-phosphate (SIP)/S1P3 signaling in cholestasis-induced liver fibrosis.

Changyong Li1, Xiangming Jiang, Lin Yang, Xihong Liu, Shi Yue, Liying Li.   

Abstract

Bioactive sphingosine 1-phosphate (S1P) and S1P receptors (S1PRs) have been implicated in many critical cellular events, including inflammation, cancer, and angiogenesis. However, the role of S1P/S1PR signaling in the pathogenesis of liver fibrosis has not been well documented. In this study, we found that S1P levels and S1P(3) receptor expression in liver tissue were markedly up-regulated in a mouse model of cholestasis-induced liver fibrosis. In addition, the S1P(3) receptor was also expressed in green fluorescent protein transgenic bone marrow (BM)-derived cells found in the damaged liver of transplanted chimeric mice that underwent bile duct ligation. Silencing of S1P(3) expression significantly inhibited S1P-induced BM cell migration in vitro. Furthermore, a selective S1P(3) receptor antagonist, suramin, markedly reduced the number of BM-derived cells during cholestasis. Interestingly, suramin administration clearly ameliorated bile duct ligation-induced hepatic fibrosis, as demonstrated by attenuated deposition of collagen type I and III, reduced smooth muscle alpha-actin expression, and decreased total hydroxyproline content. In conclusion, our data suggest that S1P/S1P(3) signaling plays an important role in cholestasis-induced liver fibrosis through mediating the homing of BM cells. Modulation of S1PR activity may therefore represent a new antifibrotic strategy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19729475      PMCID: PMC2751543          DOI: 10.2353/ajpath.2009.090037

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  44 in total

Review 1.  Sphingosine 1-phosphate signaling: providing cells with a sense of direction.

Authors:  Sarah Spiegel; Denis English; Sheldon Milstien
Journal:  Trends Cell Biol       Date:  2002-05       Impact factor: 20.808

Review 2.  Variant forms of cholestatic diseases involving small bile ducts in adults.

Authors:  W R Kim; J Ludwig; K D Lindor
Journal:  Am J Gastroenterol       Date:  2000-05       Impact factor: 10.864

3.  Simultaneous quantitative analysis of sphingoid base 1-phosphates in biological samples by o-phthalaldehyde precolumn derivatization after dephosphorylation with alkaline phosphatase.

Authors:  Jung-Kee Min; Hwan-Soo Yoo; Eun-Young Lee; Woo-Jin Lee; Yong-Moon Lee
Journal:  Anal Biochem       Date:  2002-04-15       Impact factor: 3.365

Review 4.  Liver transplantation: current status and novel approaches to liver replacement.

Authors:  E B Keeffe
Journal:  Gastroenterology       Date:  2001-02       Impact factor: 22.682

5.  Matrix metalloproteinase regulation of sphingosine-1-phosphate-induced angiogenic properties of bone marrow stromal cells.

Authors:  Borhane Annabi; Sébastien Thibeault; Ying-Ta Lee; Nathalie Bousquet-Gagnon; Nicoletta Eliopoulos; Stéphane Barrette; Jacques Galipeau; Richard Béliveau
Journal:  Exp Hematol       Date:  2003-07       Impact factor: 3.084

6.  Phosphorylation of the immunomodulatory drug FTY720 by sphingosine kinases.

Authors:  Andreas Billich; Frederic Bornancin; Piroska Dévay; Diana Mechtcheriakova; Nicole Urtz; Thomas Baumruker
Journal:  J Biol Chem       Date:  2003-09-16       Impact factor: 5.157

Review 7.  Sphingosine-1-phosphate: an enigmatic signalling lipid.

Authors:  Sarah Spiegel; Sheldon Milstien
Journal:  Nat Rev Mol Cell Biol       Date:  2003-05       Impact factor: 94.444

8.  S1P3 receptors mediate the potent constriction of cerebral arteries by sphingosine-1-phosphate.

Authors:  Salvatore Salomone; Shin-ichi Yoshimura; Uwe Reuter; Melissa Foley; Sunu S Thomas; Michael A Moskowitz; Christian Waeber
Journal:  Eur J Pharmacol       Date:  2003-05-23       Impact factor: 4.432

9.  Heme oxygenase-1 is an antifibrogenic protein in human hepatic myofibroblasts.

Authors:  Liying Li; Pascale Grenard; Jeanne Tran Van Nhieu; Boris Julien; Ariane Mallat; Ada Habib; Sophie Lotersztajn
Journal:  Gastroenterology       Date:  2003-08       Impact factor: 22.682

10.  The development and compensation of biliary cirrhosis in interleukin-6-deficient mice.

Authors:  T Ezure; T Sakamoto; H Tsuji; J G Lunz; N Murase; J J Fung; A J Demetris
Journal:  Am J Pathol       Date:  2000-05       Impact factor: 4.307

View more
  44 in total

1.  FTY720, a sphingosine-1 phosphate receptor modulator, improves liver fibrosis in a mouse model by impairing the motility of bone marrow-derived mesenchymal stem cells.

Authors:  Yaxian Kong; Hong Wang; Shuling Wang; Na Tang
Journal:  Inflammation       Date:  2014-08       Impact factor: 4.092

2.  Analysis of sphingolipids in human corneal fibroblasts from normal and keratoconus patients.

Authors:  Hui Qi; Shrestha Priyadarsini; Sarah E Nicholas; Akhee Sarker-Nag; Jeremy Allegood; Charles E Chalfant; Nawajes A Mandal; Dimitrios Karamichos
Journal:  J Lipid Res       Date:  2017-02-10       Impact factor: 5.922

3.  Suramin decreases injury and improves regeneration of ethanol-induced steatotic partial liver grafts.

Authors:  Songqing He; Hasibur Rehman; Yanjun Shi; Yasodha Krishnasamy; John J Lemasters; Rick G Schnellmann; Zhi Zhong
Journal:  J Pharmacol Exp Ther       Date:  2012-11-16       Impact factor: 4.030

Review 4.  Therapeutic targets for cholestatic liver injury.

Authors:  Benjamin L Woolbright; Hartmut Jaeschke
Journal:  Expert Opin Ther Targets       Date:  2015-10-19       Impact factor: 6.902

5.  FTY720/fingolimod decreases hepatic steatosis and expression of fatty acid synthase in diet-induced nonalcoholic fatty liver disease in mice.

Authors:  Timothy D Rohrbach; Amon Asgharpour; Melissa A Maczis; David Montefusco; L Ashley Cowart; Pierre Bedossa; Arun J Sanyal; Sarah Spiegel
Journal:  J Lipid Res       Date:  2019-05-20       Impact factor: 5.922

6.  Suramin inhibits renal fibrosis in chronic kidney disease.

Authors:  Na Liu; Evelyn Tolbert; Maoyin Pang; Murugavel Ponnusamy; Haidong Yan; Shougang Zhuang
Journal:  J Am Soc Nephrol       Date:  2011-05-26       Impact factor: 10.121

Review 7.  Targeting sphingosine-1-phosphate receptors in cancer.

Authors:  Rebecca J Watters; Hong-Gang Wang; Shen-Shu Sung; Thomas P Loughran; Xin Liu
Journal:  Anticancer Agents Med Chem       Date:  2011-11       Impact factor: 2.505

8.  The class D scavenger receptor CD68 contributes to mouse chronic liver injury.

Authors:  Le Yang; Lin Yang; Chengbin Dong; Liying Li
Journal:  Immunol Res       Date:  2018-06       Impact factor: 2.829

9.  Delayed administration of suramin attenuates the progression of renal fibrosis in obstructive nephropathy.

Authors:  Na Liu; Evelyn Tolbert; Murugavel Ponnusamy; Haidong Yan; Shougang Zhuang
Journal:  J Pharmacol Exp Ther       Date:  2011-05-27       Impact factor: 4.030

10.  Sphingosine 1-phosphate (S1P) receptor agonists mediate pro-fibrotic responses in normal human lung fibroblasts via S1P2 and S1P3 receptors and Smad-independent signaling.

Authors:  Katrin Sobel; Katalin Menyhart; Nina Killer; Bérengère Renault; Yasmina Bauer; Rolf Studer; Beat Steiner; Martin H Bolli; Oliver Nayler; John Gatfield
Journal:  J Biol Chem       Date:  2013-04-15       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.